
Opinion|Videos|May 28, 2025
Navigating the Heterogeneous Progression of Duchenne Muscular Dystrophy
Author(s)Diana Castro, MD
Duchenne Muscular Dystrophy progresses with motor delays, varying deterioration rates, and impacts multiple organs, highlighting the need for early intervention.
Advertisement
Episodes in this series

Summary for Physicians
Disease Progression in Duchenne Muscular Dystrophy (DMD)DMD
DMD progresses in stages, with initial motor milestone delays and a gradual loss of motor function. Key points include the following:
- Early delays in motor milestones like such as standing, walking, running, and climbing stairs.
- Maximum motor capacity typically achieved by age 6.5½, followed by a noticeable decline in function. Some children may lose the ability to walk as early as age 7 to -8 years, while others may progress more slowly.
- Wide range of progression: Some mutations (e.g.eg, those amenable to Eexon 44 skipping) may result in slower progression and less severe weakness.
- Dystrophin deficiency leads to muscle cell damage and affects multiple organs, including the heart, lungs, and digestive system, contributing to the disease's progressive nature.
- Respiratory and cardiac involvement develop with age, and early death was common before the use of steroids and other therapies.
- Prognosis improvement: With steroids and new therapies, life expectancy has increased, and newborn screening may further improve outcomes by enabling earlier interventions.
Advertisement
Related to this article

Ocrelizumab demonstrated noninferiority to fingolimod for relapse control but displayed greater reductions in MRI lesion activity among pediatric patients with relapsing-remitting multiple sclerosis.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Ocrelizumab Shows MRI Benefits vs Fingolimod in Phase 3 Pediatric-Onset Multiple Sclerosis Study
2
The Road Ahead for Precision Medicine in Multiple Sclerosis
3
ELEVIDYS Shows Functional Benefits in Patients With DMD, Dompé Launches Phase 2 Trial of Intranasal Nerve Growth Factor in CP, NeurologyLive Roundtable: The Road Ahead for Precision Medicine in MS
4
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
5




